Author Index

Ambrose, M.W., see Wyde, P.R., 15
Amicucci, P., see Dianzani, F., 299
Antonelli, G., see Dianzani, F., 299
Antonelli, G., see Ruggiero, V., 77

Baba, M., see Nakashima, H., 233
Balzarini, J., Herdewijn, P. and De Clercq, E.
  Potentiating effect of ribavirin on the anti-retrovirus activity of 3′-azido2,6-diaminopurine-2′,3′-dideoxyriboside in vitro and in vivo, 161
Bernstein, D.I., see Starberry, L.R., 215
Bernstein, D.I., see Reuman, P.D., 27
Brisebois, J.J., Dumas, V.M. and Joncas, J.H.
  Comparison of two methods in the determination of the sensitivity of 84 herpes simplex virus (HSV) type 1 and 2 clinical isolates to acyclovir and alpha-interferon, 67
Brjantseva, E.A., see Kubar, O.I., 313
Brown, J.W., see Pontani, D.R., 119
Burke, R.L., see Starberry, L.R. 215
Burns, M., see Herrmann, J.E., 127

Capobianchi, M.R., see Dianzani, F., 299
Chang, R.S., see Tabba, H.D., 263
Collins, P., see Zwartouw, H.T., 279
Conciatori, G., see Ruggiero, V., 77

Davarsky, K.A., see Schuster, G., 307
De Clercq, E., see Balzarini, J., 161
De Clercq, E., see Nakashima, H., 233
De Man, R.A., Lindemans, J., Schalm, S.W. and Ten Kate, F.J.W.
  β_2-Microglobulin and antiviral therapy for chronic hepatitis type B, 181
De Marco, F., see Dianzani, F., 299
Debs, R.J., see Shanley, J.D., 99
Dianzani, F., Capobianchi, M.R., Antonelli, G., Amicucci, P. and De Marco, F.
  Susceptibility of human immunodefidiency virus to antiviral agents measured by infectious virus yield reduction (Short Communication), 299
Dianzani, F., see Ruggiero, V., 77
Divizia, M., see Superti, F., 247
Dumas, V.M., see Brisebois, J.J., 67

Ennis, F.A., see Herrmann, J.E., 127

Farkas, I., see Nagy, P.D., 41
Frazer, J., see Garcon, N.M., 89
Fujimaki, M., see Hattori, T., 255
Fukuchi, K., Sakagami, H., Okuda, T., Hatano, T., Tanuma, S.-i., Ynoue, Y., Inoue, S., Ichikawa, S., Nonoyama, M. and Konno, K.
  Inhibition of herpes simplex virus infection by tannins and related compounds, 285

Gáborjányi, R., see Nagy, P.D., 41
Gabrieli, R., see Superti, F., 247
Garcon, N.M., Six, H.R., Frazer, J., Hazlewood, C., Gilbert, B.E. and Knight, V.
  Liposomes of enviroxime and phosphatidylcholine: definition of the drug-phospholipid interactions, 89
Gentile, M., see Ruggiero, V., 77
Gilbert, B.E., see Garcon, N.M., 89
Gilbert, B.E., see Wyde, P.R., 15

Hada, M., see Hattori, T., 255
Harrison, C.J., see Starberry, L.R., 215
Hasegawa, A., see Ikeda, S., 173
Hatano, T., see Fukuchi, K., 285
Hattori, T., Ikematsu, S., Koito, A., Matsushita, S., Maeda, Y., Hada, M., Fujimaki, M. and Takatsuki, K.
  Preliminary evidence for inhibitory effect of glycyrrhizin on HIV replication in patients with AIDS, 255
Hazlewood, C., see Garcon, N.M., 89
Herdewijn, P., see Balzarini, J., 161
Herrmann, J.E., Burns, M., West, K. and Enniss, F.A.
  Efficacy of rimantadine hydrochloride in the treatment of influenza infection of mice, 127
Hill, D.L., see Zeidner, N.S., 147
Homma, J.Y., see Ideka, S., 173
Hoover, E.A., see Zeidner, N.S., 147
Hsiung, G.D., see Hu, J.M., 217
Hu, J.M. and Hsiung, G.D.
  Evaluation of new antiviral agents: I. In vitro perspectives, 217
Humphreys, C.R., see Zwartouw, H.T., 279

Ichikawa, S., see Fukuchi, K., 285
Ikeda, S., Tominaga, T., Nishimura, C., Homma, J.Y., Kiso, M. and Hasegawa, A.
  Antiherpes activity of chemically synthesized lipid A-subunit analogue GLS-60 in immunosuppressed mice, 173
Ikematsu, S., see Hattori, T., 255

Inoue, S., see Fukuchi, K., 285
Inoue, Y., see Fukuchi, K., 285
Inoue, Y., p. 325

Joncas, J.H., see Brisebois, J.J., 67

Keefer, M.C., see Reuman, P.D., 27
Kiso, M., see Ikeda, S., 173
Knight, V., see Garcon, N.M., 89
Koito, A., see Hattori, T., 255
Konno, K., see Fukuchi, K., 285
Kopecka, H., see Lopez Pila, J.M., 47
Kovács, L., see Nagy, P.D., 41
Kubar, O.I., Brjantseva, E.A., Nikitina, L.E. and Zlydnikov, D.M.
The importance of virus drug-resistance in the treatment of influenza with rimantadine, 313

Lindemans, J., see De Man, R.A., 181
Lopez Pila, J.M., Kopecka, H. and Vanden Berghe, D.
Lack of evidence for strand-specific inhibition of poliovirus RNA sysnthesis by 3-methylquercetin (Short Communication), 47
Lopez-Bernstein, G., see Pontani, D.R., 119

Meada, Y., see Hattori, T., 255
Matsushita, S., see Hattori, T., 255
Mitchell, .M., see Montefiori, D.C., 137
Montefiori, D.C., Robinson, Jr., W.E. and Mitchell, W.M.
Antibody-independent, complement-mediated enhancement of HIV-1 infection by mannoside I and II inhibitors, 137
Morse, G.D., Olson, J., Portmore, A., Taylor, C., Plank, C. and Reichman, R.C.
Pharmacokinetics of orally administered zidovudine among patients with hemophilia and asymptomatic human immunodeficiency virus (HIV) infection, 57
Mullins, J.I., see Zeidner, N.S., 147
Myers, M.M., see Starberry, L.R., 215

Nagy, P.D., Gáborjányi, R., Kovács, L. and Farkas, I.
Antiviral activity of tiazofurine against barley stripe mosaic virus (Short Communication), 41
Nakashima, H., Yoshida, O., Baba, M., De Clercq, E. and Yamamoto, N.
Anti-HIV activity of dextran sulphate as determined under different experimental conditions, 233
Nikitina, L.E., see Kubar, O.I., 313
Nishimura, C., see Ikeda, S., 173
Nokta, M.A. and Pollard, R.B.
Differential reconstitution of zidovudine-induced inhibition of mitogenic responses by interleukin-2 in peripheral blood mononuclear cells from patients with human immunodeficiency virus infection, 191
Nonoyama, M., see Fukichi, K., 295

Okuda, T., see Fukuchi, K., 285
Olson, J., see Morse, G.D., 57
Orsi, N., see Superti, F., 247
Ott, G., see Starberry, L.R., 215

Panà, A., see Superti, F., 247
Perigo, N.A., see Zeidner, N.S., 147
Plank, C., see Morse, G.D., 57
Plescia, O.J., see Pontani, D.R., 119
Pollard, R.B., see Nokta, M.A., 191
Pontani, D.R., Sun, D., Brown, J.W., Shahied, S.I., Plescia, O.J., Schaffner, C.P., Lopez-Bernstein, G. and Sarin, P.S.
Inhibition of IV replication by liposomal encapsulated amphotericin B, 119
Portmore, A., see Morse, G.D., 57

Reichman, R.C. and Strike, D.G.
Pathogenesis and treatment of human genital papillomavirus infections: a review, 109
Reichman, R.C., see Morse, G.D., 57
Reuman, P.D., Bernstein, D.I., Keefer, M.C., Young, E.C., Sherwood, J.R. and Sciff, G.M.
Efficacy and safety of low dosage amantadine hydrochloride as prophylaxis for influenza A, 27
Robinson, Jr., W.E., see Montefiori, D.C., 137
Rossman, M.G.
The structure of antiviral agents that inhibit uncoating when complexed with viral capsids, 3
Ruggiero, V., Antonelli, G., Conciatori, G., Gentile, M., Van Damme, J. and Dianzani, F.
The in vitro antiviral activity of tumor necrosis factor (TNF) in WISH cells is mediated by IFN-β induction, 77

Sakagami, H., see Fukuchi, K., 285
Sarin, P.S., see Pontani, D.R., 119
Schaffner, C.P., see Pontani, D.R., 119
Schalm, S.W., see De Man, E.A., 181
Schiff, G.M., see Reuman, P.D., 27
Schuster, G., Davarsky, K.A. and Vassilev, G.N.

Enhanced inhibition of plant virus replication by pyridylthiourea compounds complexed with metal ions (Short Communication), 307

Seganti, L., see Superti, F., 247

Shahied, S.I., see Pontani, D.R., 119

Shanley, J.D. and Debs, R.J.
the folate antagonist, methotrexate, is a potent inhibiytor of murine and human cytomegalovirus in vitro, 99

Sherwood, J.R., see Reuman, P.D., 27

Shukla, R., see Starberry, L.R., 215

Six, H.R., see Garcon, N.M., 89

Smith, K.M., see Tabba, H.D., 263

Starberry, L.R., Harrison, C.J., Bernstein, D.I., Burke, R.L., Shukla, R., Ott, G. and Myers, M.M.
Herpes simplex glycoprotein immunotherapy of recurrent genital herpes: factors influencing efficacy, 215

Stein, P.L., see Superti, F., 247

Strike, D.G., see Reichman, R.C., 109

Strobel, J.D., see Zeidner, N.S., 147

Sun, D., see Pontani, D.R., 119

Superti, F., Seganti, L., Orsi, N., Divizia, M., Gabrieli, R., Panà, A., and Stein, P.L.
Effect of isoflavans and isoflavenes on the infection of Frp/3 cells by hepatitis A virus, 247

Tabba, H.D., Chang, R.S. and Smith, K.M.
Isolation, purification, and partial characterization of prunellin, an anti-HIV component from aqueous extracts of *Prunella vulgaris*, 263

Takatsuki, K., see Hattori, T., 255

Tanuma, S.-i., see Fukuchi, K., 285

Taylor, C., see Morse, G.D., 57

Ten Kate, F.J.W., see De Man, R.A., 181

Tominaga, T., see Ikeda, S., 173

Van Damme, J., see Ruggiero, V., 77

Vanden Berghe, D., see Lopez Pila, J.M., 47

Vassilev, G.N., see Schuster, G., 307

West, K., see Herrmann, J.E., 127

Wyde, P.R., Gilbert, B.E. and Ambrose, M.W.
Comparison of the anti-respiratory syncytical virus activity and toxicity of papaverine hydrochloride and pyrazofurin in vitro and in vivo, 15

Yamamoto, N., see Nakashima, H., 233

Yoshida, O., see Nakashima, H., 233

Young, E.C., see Reuman, P.D., 27

Zeidner, N.S., Strobel, J.D., Perigo, N.A., Hill, D.L., Mullins, J.I. and Hoover, E.A.
Treatment of FeLV-induced immunodeficiency syndrome (FeLV-FAIDS) with controlled release capsular implantation of 2′-3′-dideoxycytidine, 147

Zlydnikov, D.M., see Kubar, O.I., 313

Zwartouw, H.T., Humphreys, C.R. and Collins, P.
Oral chemotherapy of fatal B virus (herpes virus simiae) infection, 279

Subject Index

AIDS, HIV-1, Glycyrrhizin, Antigen, p24, 255
AIDS, ZDV, IL-2, HIV, 191
Acyclovir, Herpes simplex virus, α-Interferon, Sensitivity, 67
Acyclovir, Herpes simplex virus type 1, Ganciclovir, B virus
Aerosol, Enviroxime, Liposome, Lecithin, 89
Amphotericin B, Inhibition of HIV replication, Liposomal encapsulated drug, 119
Anti-HIV activity, Dextran sulphate, Anti-HIVC-1 serum, Sulphated polysaccharide, 233
Anti-HIV compound, *Prunella vulgaris*, Polysaccharide, Purification, Chromatography, Spectroscopy, 263
Anti-HIV-1 serum, Anti-HIV activity, Dextran sulphate, Sulphated polysaccharide, 233
Antigen, p24, AIDS, HIV-1, Glycyrrhizin, 255
Antiparallel β-barrel, Hydrophobic pocket, Viral capsid protein, Inhibition of uncoating, 3
Antiphytoviral substance, Pyridylthiourea, 2,4-Dioxohexahydro-1,3,5-triazine, Potato virus X, 307
Antiviral therapy, Feline leukemia virus, Immunodeficiency, 147
Antiviral therapy, Hepatitis B, β_2-Microglobulin, HBV-DN1-polymerase, 181
Antiviral agent, Chemotherapy, Test method, 217
3′ -Azido-2,6-diaminopurine-2′,3′-dideoxyriboside (AzddDAPR), Ribavirin, 2′;3′-Dideoxynucleoside, Human immunodeficiency virus (HIV), Moloney murine sarcoma virus (MSV), 161

Barley stripe mosaic virus, Plant virus, Tiazofurine, 41

Chemotherapy, Antiviral agent, Test method, 217
Chromatography, *Prunella vulgaris*, Polysaccharide, Anti-HIV compound, Purification, Spectroscopy, 263
Complement, HIV infection-enhancement, Glycosylation, 137

Dextran sulphate, Anti-HIV activity, Anti-HIV-1 serum, Sulphated polysaccharide, 233
6,4′-Dichloroflavan, Hepatitis A virus, Isoflavan, isoflavene, 247
2,′3′-Dideoxynucleoside, 3′-Azido-2,6-diaminopurine-2′,3′-diceoxyriboside (AzddDAPR), Ribavirin, Human immunodeficiency virus (HIV), Moloney murine sarcoma virus (MSV), 161
2,4-Dioxohexahydro-1,3,5-triazine, Antiphytoviral substance, Pyridylthiourea, Potato virus X, 307

Enviroxime, Liposome, Aerosol, Lecithin, 89

Feline leukemia virus, Immunodeficiency, Antiviral therapy, 147

Gaanciclovir, Herpes simplex virus type 1, Acyclovir, B virus
Genital herpes, HSV-1, Glycoprotein, Guinea pig, 203
Glycoprotein, HSV-1, Genital herpes, Guinea pig, 203
Glycosylation, HIV infection-enhancement, Complement, 137
Glycyrrhizin, AIDS, HIV-1, Antigen, p24, 255
Guanidine, Poliovirus, 3-Methylquercetin, Plus-strand RNA, Minus-strand RNA, 47
Guinea pig, HSV-1, Glycoprotein, Genital herpes, 203

HBV-DNA-polymerase, Hepatitis B, Antiviral therapy, β_2-Microglobulin, 181
HIV infection-enhancement, glycosylation, Complement, 137
HIV, Susceptibility to antiviral agents, 299
HIV, ZDV, IL-2, AIDS, 191
HIV-1, AIDS, Glycyrrhizin, Antigen, p25, 255
HPV infection, Pathogenesis, 109
HSV-1, Glycoprotein, Genital herpes, Guinea pig, 203
Hemophilia, Zidovudine, Human immunodeficiency virus infection, 57
Hepatitis A virus, Isoflavan, Isoflavene, 6,4′-Dichloroflavan, 247
Hepatitis B, Antiviral therapy, β_2-Microglobulin, HBV-DNA-polymerase, 181
Herpes simplex virus, Acyclovir, α-Interferon, Sensitivity, 67
Herpes simplex virus, Lipid A analogue, Immunocompromised host, Immunomodulator, 173
Herpes simplex virus type 1, Acyclovir, Ganciclovir, B virus
Herpes simplex virus, Tannin, Virus adsorption, 285

Human cytomegalovirus, Methotrexate, Murine cytomegalovirus, 99
Human immunodeficiency virus infection, Zidovudine, Hemophilia, 57
Human immunodeficiency virus (HIV), 3′-Azido-2,6-diaminopurine-2′,3′-dideosyriboside (AzddDAPR), Ribavirin, 2,′3′-Dideoxynucleoside, Moloney murine sarcoma virus (MSV), 161
Hydrophobic pocket, Viral capsid protein, Antiparallel β-barrel, Inhibition of uncoating, 3

IFN-B$_2$, TNF, IL-6, 2-5A synthetase, 77
IL-6, TNF, IFN-B^2, 2-5A synthetase, 77
IL-2, ZDV, AIDS, HIV, 191
Immunocompromised host, Lipid A analogue, Herpes simplex virus, Immunomodulator, 173
Immunodeficiency, Feline leukemia virus, Antiviral therapy, 147
Immunomodulator, Lipid A analogue, Herpes simplex virus, Immunocompromised host, 173
Influenza A, Low dose amantadine, 27
Influenza A virus, Rimantadine HCl, 127
Influenza A, Rimantadine, Virus drug-resistance, 313
Inhibition of uncoating, Hydrophobic pocket, Viral capsid protein, Antiparallel β-barrel, 3
Inhibition of HIV replication, Amphotericin B, Liposomal encapsulated drug, 119
α-Interferon, Herpes simplex virus, Acyclovir, Sensitivity, 67
Isoflavan, Hepatitis A virus, Isoflavene, 6,4′-Dichloroflavan, 247
Isoflavene, Hepatitis A virus, Isoflavan, 6,4′-Dichloroflavan, 247

Lecithin, Enviroxime, Liposome, Aerosol, 89
Lipid A analogue, Herpes simplex virus, Immunocompromised host, Immunomodulator, 173
Liposomal encapsulated drug, amphotericin B, Inhibition of HIV replication, 119
Liposome, Enviroxime, Aerosol, Lecithin, 89
Low dose amantadine, Influenza A, 27

Methotrexate, Human cytomegalovirus, Murine cytomegalovirus, 99
3-Methylquercetin, Poliovirus, Guanidine, Plus-strand RNA, Minus-strand RNA, 47
B$_2$-Microglobulin, Hepatitis B, Antiviral therapy, HBV-DNA-polymerase, 181
Minus-strand RNA, Poliovirus, 3-Methylquercetin, Guanidine, Plus-strand RNA, 47
Moloney murine sarcoma virus (MSV), 3′-Azido-2,6-diaminopurine-2′,3′-dideoxyriboside (AzddDAPR), Ribavirin, 2,′3′-Dideoxynucleoside, Human immunodeficiency virus (HIV), 161
Murine cytomegalovirus, Methotrexate, Human cytomegalovirus, 99

Papaverine, Pyrazofurin, Respiratory syncytial virus, 15
Pathogenesis, HPV infection, 109
Plant virus, Barley stripe mosaic virus, Tiazofurine, 41
Plus-strand RNA, Poliovirus, 3-Methylquercetin, Guanidine, Minus-strand RNA, 47
Poliovirus, 3-Methylquercetin, Guanidine, Plus-strand RNA, Minus-strand RNA, 47
Polysaccharide, *Prunella vulgaris*, Anti-HIV compound, Purification, Chromatography, Spectroscopy, 263
Potato virus X, Antiphytoviral substance, Pyridylthiourea, 2,4-Dioxohexahydro-1,3,5-triazine, 307
Prunella vulgaris, Polysaccharide, Anti-HIV compound, Purification, Chromatography, Spectroscopy, 263
Purification, *Prunella vulgaris*, Polysaccharide, Anti-HIV compound, Chromatography, Spectroscopy, 263
Pyrazofurin, Papaverine, Respiratory syncytial virus, 15
Pyridylthiourea, Antiphytoviral substance, 2,4-Dioxohexahydro-1,3,5-triazine, Potato virus X, 307

Respiratory syncytial virus, Pyrazofurin, Papaverine, 15
Ribavirin, 3′-Azido-2,6-diaminopurine-2′,3′-dideoxyriboside (AzddDAPR), 2,′3′-Dideoxynucleoside, Human Immunodeficiency virus (HIV), Moloney murine sarcoma virus (MSV), 161
Rimantadine HCl, Influenza A virus, 127
Rimantadine, Influenza A, Virus drug-resistance, 313

Sensitivity, Herpes simplex virus, Acyclovir, α-Interferon, 67
Spectroscopy, Prunella vulgaris, Polysaccharide, Anti-HIV compound, Purification, Chromatography, 263
Sulphated polysaccharide, Anti-HIV activity, Dextran sulphate, anti-HIV-1 serum, 233
Susceptibility to antiviral agents, HIV, 299
2-5A synthetase, TNF, IFN-B$_2$, IL-6, 77

TNF, IFN-B_2, IL-6, 2-5A synthetase, 77
Tannin, Herpes simplex virus, Virus adsorption, 285
Test method, Chemotherapy, Antiviral agent, 217
Tiazofurine, Plant virus, Barley stripe mosaic virus, 41
Viral capsid protein, Hydrophobic pocket, Antiparallel B-barrel, Inhibition of uncoating, 3
Virus adsorption, Tannin, Herpes simplex virus, 285
Virus drug-resistance, Rimantadine, Influenza A, 313

ZDV, IL-2, AIDS, HIV, 191
Zidovudine, Hemophilia, Human immunodeficiency virus infection, 57